Regional and temporal variation in the treatment of rheumatoid arthritis across the UK: a descriptive register-based cohort study

Objectives To describe current disease-modifying antirheumatic drugs (DMARDs) prescription in rheumatoid arthritis (RA) with reference to best practice and to identify temporal and regional trends in the UK. Design Descriptive, register-based cohort study. Participants Permanently registered patients aged ≥18 years with a recorded diagnosis of RA between 1 January 1995 and 31 March 2010 and matched controls. Participants with RA were identified through screening of all patients in the General Practice Research Database (GPRD) with a clinical or referral record for RA and at least 1 day of follow-up. Setting 639 general practices in the UK supplying data to the GPRD. Main outcome measures Medication prescribing between 3 and 12 months of RA diagnosis by region and time period (1995–1999, 2000–2005 and 2006–April 2010). Results Of the 35 911 patients in the full RA cohort, 15 259 patients (42%) had incident RA. Analysis of prescribing in incident RA patients demonstrated that between 1995 (baseline) and 2010 there was a substantial increase in DMARD, and specifically methotrexate, prescribing across all regions with a less marked increase in combination DMARD prescribing. Taking 12-month prescribing as a snapshot: DMARD prescribing was 19–49% at baseline increasing to 45–74% by 2006–April 2010; methotrexate prescribing was 4–16% at baseline increasing to 32–60%; combination DMARD prescribing was 0–8% at baseline increasing to 3–17%. However, there was marked regional variation in the proportion of RA patients receiving DMARD regardless of time period. Conclusions There has been a substantial increase in prescribing of DMARDs for RA since 1995; however, regional variation persists across the UK with relative undertreatment, according to established best practice. Improved implementation of evidence-based best clinical practice to facilitate removal of treatment variation is warranted. This may occur as a result of the implementation of published national guidance.

[1]  J. Kremer,et al.  Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. , 2012, Arthritis & Rheumatism.

[2]  J. Singh,et al.  Newer Biological Agents in Rheumatoid Arthritis , 2012, Drugs.

[3]  Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate , 2011, Arthritis care & research.

[4]  R. Fleischmann.  Don't forget traditional DMARDs. , 2011, Rheumatology.

[5]  J. Thom,et al.  Benefits of Exercise in Rheumatoid Arthritis , 2011, Journal of aging research.

[6]  N. Ovayolu,et al.  Health-related quality of life in ankylosing spondylitis, fibromyalgia syndrome, and rheumatoid arthritis: a comparison with a selected sample of healthy ındividuals , 2011, Clinical Rheumatology.

[7]  S. le Cessie,et al.  Improved treatment strategies reduce the increased mortality risk in early RA patients. , 2010, Rheumatology.

[8]  G. Jürgens,et al.  Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. , 2010, Arthritis and rheumatism.

[9]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[10]  P. Kiely,et al.  The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. , 2010, Rheumatology.

[11]  M. Suarez‐Almazor,et al.  Biologics for rheumatoid arthritis: an overview of Cochrane reviews. , 2010, Sao Paulo medical journal = Revista paulista de medicina.

[12]  D. M. van der Heijde,et al.  Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature , 2008, Annals of the rheumatic diseases.

[13]  L. Smeeth,et al.  How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? , 2008, Arthritis and rheumatism.

[14]  V. Farewell,et al.  Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[15]  P. Emery,et al.  Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment , 2006, Annals of the rheumatic diseases.

[16]  M. Liang,et al.  Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. , 2006, Arthritis and rheumatism.

[17]  C. Cooper,et al.  The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. , 2005, Rheumatology.

[18]  E. Choy,et al.  The consequences of rheumatoid arthritis: quality of life measures in the individual patient. , 2005, Clinical and experimental rheumatology.

[19]  G. Newsome.  Guidelines for the management of rheumatoid arthritis: 2002 update. , 2002, Journal of the American Academy of Nurse Practitioners.

[20]  R. Yood,et al.  Guidelines for the management of rheumatoid arthritis: 2002 Update. , 2002, Arthritis and rheumatism.

[21]  J. Wong,et al.  Long-term morbidity, mortality, and economics of rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[22]  A. Zwinderman,et al.  Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. , 2001, The American journal of medicine.

[23]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[24]  R. Lawrenson,et al.  Clinical information for research; the use of general practice databases. , 1999, Journal of public health medicine.

[25]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[26]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.